Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 113-119, February 2010

Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome

  • I-Chih Chen

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Division of Cardiology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan
    • ,
  • Ting-Hsing Chao

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    • Department of Internal Medicine, National Cheng Kung University Hospital Dou-Liou Branch, Dou-Liou, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Ting-Hsing Chao, Division of Cardiology, Department of Internal Medicine, National Cheng Kung University College of Medicine and Hospital, 138 Sheng Li Road, Tainan, Taiwan
    • ,
  • Wei-Chuan Tsai

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan
    • ,
  • Yi-Heng Li

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan
    • Cardiovascular Research Center, National Cheng Kung University College of Medicine and Hospital, Tainan, Taiwan

Received 18 February 2009; received in revised form 5 April 2009; accepted 24 June 2009.

Article Outline

Background/Purpose

Thiazolidinediones have anti-atherothrombotic effects in diabetic patients. However, the effects of rosiglitazone on inflammatory and hemostatic markers, as well as global endothelial function in non-diabetic smokers are unknown.

Methods

Twenty-seven healthy male heavy smokers without metabolic syndrome were enrolled in this double-blind, controlled study. Fourteen subjects received 4 mg/day rosiglitazone for 8 weeks (group R) and 13 subjects received placebo (group C). Changes in the reflection index (ΔRI) of β-agonist-induced endothelium-dependent vasodilatation by photoplethysmography and plasma biomarkers were measured before and after treatment.

Results

Matrix metalloproteinase-9, fibrinogen, and high-sensitivity C-reactive protein were reduced significantly in group R after treatment as compared with the baseline [84.1 (45.6 139.0) vs. 123.9 (58.4 141.8) ng/mL, p = 0.03; 2914 (2400-3553) vs. 3220 (2542-3940) mg/L, p = 0.04; and 3.4 (2.2 5.1) vs. 5.5 (4.1 6.8) mg/L, p = 0.009, respectively]. ΔRI was improved markedly in group R as compared with the baseline [13.5 (4.2 65.1) vs. 2.5 (−10.6 to 9.3)%; p = 0.024]. These biomarkers and ΔRI did not differ significantly in the group C. There were no significant changes in fasting plasma glucose, insulin, homeostasis model assessment index, and lipid profile in both groups R and group C.

Conclusion

Rosiglitazone significantly reduces plasma levels of inflammatory and hemostatic biomarkers, and restores global endothelial dysfunction, independently from insulin sensitization, in healthy smokers.

Key Words:  endothelium , metabolic syndrome , peroxisome proliferator-activated receptor , rosiglitazone , smoking

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Raskin P , Rappaport EB , Cole ST , et al.   Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes . Diabetologia . 2000;43:278–284
  2. Parulkar AA , Pendergrass ML , Granda-Ayala R , et al.   Non-hypoglycemic effects of thiazolidinediones . Ann Intern Med . 2001;134:61–71
  3. Duan SZ , Usher MG , Mortensen RM . Peroxisome prolifer-ator-activated receptor-gamma-mediated effects in the vasculature . Circ Res . 2008;102:283–294
  4. Tseng CH , Huang TS . Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients . Diabetes Res Clin Pract . 2005;70:193–194
  5. Haffner SM , Greenberg AS , Weston WM , et al.   Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes melli-tus . Circulation . 2002;106:679–684
  6. Nordt TK , Peter K , Bode C , et al.   Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells . J Clin Endocrinol Metab . 2000;85:1563–1568
  7. Marx N , Froehlich J , Siam L , et al.   Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease . Arterioscler Thromb Vasc Biol . 2003;23:283–288
  8. Randriamboavonjy V , Pistrosch F , Bölck B , et al.   Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone . Circulation . 2008;117:52–60
  9. Yu J , Jin N , Wang G , et al.   Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease . Metabolism . 2007;56:1396–1401
  10. Rosmarakis ES , Falagas ME . Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials . Am Heart J . 2007;154:144–150
  11. Sorrentino SA , Bahlmann FH , Besler C , et al.   Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes melli-tus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone . Circulation . 2007;116:163–173
  12. Raji A , Seely EW , Bekins SA , et al.   Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients . Diabetes Care . 2003;26:172–178
  13. Wang TD , Chen WJ , Lin JW , et al.   Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome . Am J Cardiol . 2004;93:362–365
  14. Esposito K , Ciotola M , Carleo D , et al.   Effect of rosiglita-zone on endothelial function and inflammatory markers in patients with the metabolic syndrome . Diabetes Care . 2006;29:1071–1076
  15. Chinetti G , Fruchart JC , Staels B . Peroxisome proliferators-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation . Inflamm Res . 2000;49:497–505
  16. Inoue I , Katayama S , Takahashi K , et al.   Troglitazone has a scavenging effect on reactive oxygen species . Biochem Biophys Res Commun . 1997;235:113–116
  17. Chen Z , Ishibashi S , Perrey S , et al.   Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL . Arterioscler Thromb Vasc Biol . 2001;21:372–377
  18. Li AC , Brown KK , Silvestre MJ , et al.   Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice . J Clin Invest . 2000;106:523–531
  19. Shiomi T , Tsutsui H , Hayashidani S , et al.   Pioglitazone, a peroxisome proliferators-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction . Circulation . 2002;106:3126–3132
  20. Willett WC , Green A , Stampfer MJ , et al.   Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes . N Engl J Med . 1987;317:1303–1309
  21. Li YH , Chen JH , Tsai WC , et al.   Synergic effect of thrombomodulin promoter-33G/A polymorphism and smoking on the onset of acute myocardial infarction . Thromb Haemost . 2002;87:86–91
  22. Teng JK , Lin LJ , Tsai LM , et al.   Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications . Int J Cardiol . 1994;44:29–36
  23. Zeiher AM , Schächinger V , Minners J . Long-term cigarette smoking impairs endothelium-dependent coronary artery vasodilator function . Circulation . 1995;92:1094–1100
  24. Tracy RP , Psaty BM , Macy E , et al.   Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects . Arterioscler Thromb Vasc Biol . 1997;17:2167–2176
  25. Blann AD , Steele C , McCollum CN . The influence of smoking on soluble adhesion molecules and endothelial cell markers . Thromb Res . 1997;85:433–438
  26. Sharp DS , Benowitz NL , Bath PM , et al.   Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood . Thromb Haemost . 1995;74:730–735
  27. Nakamura T , Ebihara I , Shimada N , et al.   Effect of cigarette smoking on plasma metalloproteinase-9 concentration . Clin Chim Acta . 1998;276:173–177
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults  . Executive summary of the third report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  29. Chao TH , Tsai LM , Tsai WC , et al.   Effect of atrial fibrillation on pulmonary venous flow patterns assessed by Doppler transesophageal echocardiography . Chest . 2000;117:1546–1550
  30. Matthews DR , Hosker JP , Rudenski AS , et al.   Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia . 1985;28:412–419
  31. Hijmering ML , Stroes ES , Pasterkamp G , et al.   Variability of flow mediated dilation: consequences for clinical application . Atherosclerosis . 2001;157:369–373
  32. De Roos NM , Bots ML , Schouten EG , et al.   Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies . Ultrasound Med Biol . 2003;29:401–406
  33. Malik J , Wichterle D , Haas T , et al.   Repeatability of noninvasive surrogates of endothelial function . Am J Cardiol . 2004;94:693–696
  34. McEniery CM , Wallace S , Mackenzie IS , et al.   Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans . Hypertension . 2006;48:602–608
  35. Chowienczyk PJ , Kelly RP , MacCallum H , et al.   Photoplethysmographic assessment of pulse wave reflection . J Am Coll Cardiol . 1999;34:2007–2014
  36. Hayward CS , Kraidly M , Webb CM , et al.   Assessment of endothelial function using peripheral waveform analysis. A clinical application . J Am Coll Cardiol . 2002;40:521–528
  37. Wilkinson IB , Hall IR , MacCallum H , et al.   Pulse wave analysis. Clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function . Arterioscler Thromb Vasc Biol . 2002;22:147–152
  38. Gopaul NK , Manraj MD , Hébé A , et al.   Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism . Diabetologia . 2001;44:706–712
  39. Hetzel J , Balletshofer B , Rittig K , et al.   Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers . Arterioscler Thromb Vasc Biol . 2005;25:1804–1809
  40. Dandona P , Aljada A . A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis . Am J Cardiol . 2002;90:G27–G33
  41. Chao TH , Li YH , Chen JH , et al.   The 161TT genotype in the exon 6 of peroxisome proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers . Clin Sci . 2004;107:461–466
  42. Amoruso A , Bardelli C , Gunella G , et al.   Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine . Life Sci . 2007;81:906–915
  43. Selvin E , Bolen S , Yeh HC , et al.   Cardiovascular outcomes in trials of oral diabetes medications: a systematic review . Arch Intern Med . 2008;168:2070–2080
  44. Monami M , Marchionni N , Mannucci E . Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone . Diabetes Res Clin Pract . 2008;82:48–57

PII: S0929-6646(10)60031-9

doi:10.1016/S0929-6646(10)60031-9

Journal of the Formosan Medical Association
Volume 109, Issue 2 , Pages 113-119, February 2010

Article Tools